William P Esler

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Placebo Controlled

Top Venues

Diabetes, obesity & metabolism

Clinical and translational science

Nature medicine

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Aarti Sawant-Basak, Arthur J Bergman, Jessica Mancuso, Sakambari Tripathy, James R Gosset, Laure Mendes da Costa, William P Esler, Roberto A Calle
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants. Clinical and translational science 17 (2) (2024)
Aarti Sawant-Basak, Arthur J Bergman, Jessica Mancuso, Sakambari Tripathy, James R Gosset, Laure Mendes da Costa, William P Esler, Roberto A Calle
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants. Clinical and translational science 17 (2) (2024)
Aarti Sawant-Basak, Arthur J Bergman, Jessica Mancuso, Sakambari Tripathy, James R Gosset, Laure Mendes da Costa, William P Esler, Roberto A Calle
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants. Clinical and translational science 17 (2) (2024)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Roberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez, Trenton T Ross, Arthur Bergman, Sudeepta Aggarwal, Collin Crowley, Anthony Rinaldi, Jessica Mancuso, Naresh Aggarwal, Veena Somayaji, Malgorzata Inglot, Theresa A Tuthill, Kou Kou, Magalie Boucher, Greg Tesz, Robert Dullea, Kendra K Bence, Albert M Kim, Jeffrey A Pfefferkorn, William P Esler
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nature medicine 27 (10) (2021)
William P Esler, Gregory J Tesz, Marc K Hellerstein, Carine Beysen, Raja K Sivamani, Scott M Turner, Steven M Watkins, Paul A Amor, Santos Carvajal-Gonzalez, Frank J Geoly, Kathleen E Biddle, Julie J Purkal, Mark D Fitch, Clare Buckeridge, Annette M Silvia, David A Griffith, Matthew Gorgoglione, Lauren Hassoun, Suzana S Bosanac, Nicholas B Vera, Timothy P Rolph, Jeffrey A Pfefferkorn, Gabriele E Sonnenberg
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition. Science translational medicine 11 (492) (2020)
Kenneth L Kelly, William J Reagan, Gabriele E Sonnenberg, Michelle F Clasquin, Katherine Hales, Shoh Asano, Paul A Amor, Santos Carvajal-Gonzalez, Norimitsu Shirai, Marcy D Matthews, Kelvin W Li, Marc K Hellerstein, Nicholas B Vera, Trenton T Ross, Gregg Cappon, Arthur Bergman, Clare Buckeridge, Zhongyuan Sun, Enida Ziso Qejvanaj, Theodore Schmahai, David Beebe, Jeffrey A Pfefferkorn, William P Esler
De novo lipogenesis is essential for platelet production in humans. Nature metabolism 2 (10) (2020)